Private Equity Tries to Breathe New Life into US Hospice Chain

Private equity buyers see potential to optimize Enhabit’s **hospice operations** through cost efficiencies, expanded payer contracts, and technology integration. Hospice admissions rose amid an aging U.S. population, with Medicare reimbursements supporting steady cash flows. Analysts note Enhabit’s **hospice growth strategies** have offset home health declines, positioning it for **private equity-backed hospice investments**.[1]

Enhabit’s Performance and Market Context

EHAB shares have attracted institutional interest, with stakes built by funds like Iron Triangle Partners LP (1.14 million shares), Walleye Capital LLC (39,265 shares), and Trexquant Investment LP in recent quarters.[1] Price targets vary: UBS cut to $8.50 in August 2025, while Jefferies raised to $12 with a Buy rating in May 2025, reflecting **hospice valuation trends in private equity**.[1]

The broader healthcare private equity landscape supports such moves. Ascend Capital Partners closed its $791 million Fund II in 2026, exceeding its $700 million target for healthcare investments, including potential hospice targets.[2] McKinsey reports project U.S. hospice market growth to $50 billion by 2030, driven by demographic shifts, though regulatory scrutiny on PE ownership rises.[4]

[1]

Industry Implications and Risks

This deal exemplifies **private equity exit strategies in healthcare** and **cross-border M&A trends 2025** extending into 2026, with PE firms targeting resilient subsectors like hospice amid home health reimbursement pressures. Bain & Company notes PE healthcare dry powder exceeds $300 billion, favoring **hospice chain acquisitions** for operational turnarounds.[4]

• Synergies: PE operational expertise could boost Enhabit’s 12% hospice revenue growth trajectory, per Q2 2025 results.[1]
• Risks: Regulatory probes into PE hospice roll-ups intensify, with FTC focus on quality and pricing; recent DOJ antitrust suits highlight scrutiny.[4]
• Comparables: Similar to PE buys of Amedisys (Optum, 2023) and LHC Group (UnitedHealth, 2023), emphasizing scale in end-of-life care.

Leadership transitions and potential layoffs remain undisclosed, but PE playbooks often include workforce optimization. Goldman Sachs forecasts **PE investment in hospice care** rising 15% annually through 2028, contingent on Medicare policy stability.[4]

Outlook for Investors

For C-level executives and deal advisors, Enhabit’s privatization underscores hospice as a **defensive asset class** in volatile healthcare M&A. Watch for integration milestones and reimbursement updates, as they will dictate post-deal value creation in this **private equity hospice turnaround**.